Surgical robots are medical devices that assist surgeons in performing many types of complex procedures with more accuracy, flexibility and control than is possible with conventional techniques. The aim of surgical robots market players is to provide improved diagnostic skills, a less invasive and more comfortable experience for the patient, and the ability to do minor and more accurate interventions.
Surgical robots are currently used not just for prostate surgery, but for hysterectomies, the removal of fibroids, joint replacements, open-heart surgery and kidney surgeries. They can be used along with MRIs to provide organ biopsies. The most well-known surgical robot in market is the da Vinci Surgical System. The da Vinci is typically used for minimally invasive surgery (MIS), and is often used for procedures such as hysterectomies, prostatectomies, bypass surgeries and removing cancerous tissues. Since the physician can see images of the patient and control the robot through a computer, he/she does not need to be in the room, or even at the same location as the patient.
The next big thing in this surgical robots market is autonomous surgical robots. According to researchers, allowing robots to perform surgery independently may eventually improve outcomes for patients. Surgical robots have become progressively common in the U.S., but presently available robots still need to be operated by surgeons. Recently, scientists reported that a device called the Smart Tissue Autonomous Robot (STAR) has been developed that could stitch together separate pieces of the bowel in pigs. This is the first time that a surgical robot has completed a share of an operation in living soft tissue without human management. Autonomous robots would be more reliable than humans as they might minimize the risk of human errors and enhance surgical time. However, autonomous robotic surgery has still a long way to go before it’s ready for prime time.
New players who offer more affordable robots with new technological features are all set to change the dynamics in the promising surgical robotics market, which is estimated to be worth $20 billion by 2021. Apart from the major players like Intuitive Surgical’s da Vinci Surgical System and other reputable players in the field of surgical robotics, emerging contenders are gearing up to challenge the authority in the surgical robotics market by offering agility, affordability, and hi-tech advantages.
Device maker company Research Triangle Park, N.C.-based TransEnterix is on its way to obtaining U.S. Food and Drug Administration (FDA) clearance for its SurgiBot System – a single-port, mobile, and robotically enhanced laparoscopic surgical platform, which lets the surgeon operate in the sterile field. Another device maker, Titan Medical, has lately disclosed its Single Port Orifice Robotic Technology (SPORT) surgical robot in market, which is similar to the da Vinci system with its 3D visualization and intuitive finger controls, but at an affordable rate. The company plans to launch the SPORT product in the United States in 2017.
From all current trends to dynamics of the surgical robots market along with major business aspects of the industry, reports available with RnRMarketResearch.com provide all-you-need-to-know insights for new project investments, product strategy, market entry and much more. To learn more about the surgical robots market as well as other surgical equipments research visit http://www.rnrmarketresearch.com/reports/life-sciences/medical-devices/surgical-equipment .